Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,733 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06841055RecruitingPhase 2
Pumitamig plus chemo for Stage IV lung cancer after immunotherapy
This trial tests a new investigational drug called Pumitamig (BNT327) given with chemotherapy for people with advanced non-small cell lung cancer (Stage IV) that has continued to grow after one prior treatment with immunotherapy and platinum chemotherapy. The study aims to see if this combination is safe and can help shrink the cancer.
Birmingham, AlabamaAges 18 years+ - NCT06844214RecruitingPhase 1/Phase 2
Gene therapy trial for myotonic dystrophy type 1
This trial tests a one-time gene therapy (SAR446268) for people with non-congenital myotonic dystrophy type 1. It aims to see if the treatment is safe and can improve muscle symptoms like stiffness and weakness.
Gainesville, FloridaAges 10–55 - NCT06825702RecruitingPhase 2
Testing KIO-104 eye injection for macular edema
This trial tests an eye injection called KIO-104 to treat macular edema (swelling in the center of the retina) caused by conditions like uveitis, diabetes, or vein blockage. The goal is to see if it is safe and improves vision.
Sydney, New South WalesAges 18–85 - NCT06813651RecruitingPhase 2
TBO-309 for stroke with tandem blockage
This trial tests whether adding TBO-309 to standard treatment helps people having a stroke caused by two blockages (one in the neck, one in the brain). It may limit brain damage and improve recovery.
Newcastle, New South WalesAges 18 years+ - NCT06761183RecruitingEarly Phase 1
Gene therapy for arm and leg weakness after stroke
This trial tests a new gene therapy called NXL-001 for people who still have moderate to severe arm or leg weakness 2 to 12 months after a stroke. The treatment aims to help the brain repair itself and improve movement.
Beijing, Beijing MunicipalityAges 40–75 - NCT06765733RecruitingEarly Phase 1
Testing Aleeto for multiple system atrophy (MSA)
This trial tests a new treatment called Aleeto for people with a specific type of multiple system atrophy (MSA-P) who haven't responded well to standard Parkinson's medications. The goal is to see if Aleeto is safe and might help improve symptoms.
Beijing, Beijing MunicipalityAges 30–75 - NCT06695026RecruitingPhase 1/Phase 2
Testing a new combination therapy for liver cancer
This trial tests a new drug, RZ-001, combined with valganciclovir, atezolizumab, and bevacizumab for people with hepatocellular carcinoma (a type of liver cancer). The goal is to see if this combination is safe and works better than current treatments.
BusanAges 18 years+ - NCT06747858RecruitingPhase 2
Testing a new inhaler medicine for cystic fibrosis
This study tests an experimental inhalable medicine called ARCT-032 for people with cystic fibrosis who cannot take or benefit enough from current CFTR modulators. The goal is to see if it safely improves lung function and quality of life.
Tucson, ArizonaAges 18 years+ - NCT06712654RecruitingPhase 2
Testing AP306 for high phosphate in dialysis patients
This trial tests a new medication called AP306 for people on hemodialysis who have high blood phosphate. It aims to see if the drug is safe, tolerable, and helps lower phosphate levels.
Huntsville, AlabamaAges 18 years+ - NCT06699771RecruitingPhase 1
Safety study of GCC2005 for NK and T-cell cancers
This trial tests a new drug called GCC2005 for people with certain types of NK or T-cell cancers that have come back or not responded to at least two previous treatments. The goal is to see if it is safe and if it can help shrink tumors.
Seoul, SeoulAges 19–80 - NCT06690203Enrolling by invitation
Herbal Medicine for Chronic Lung Conditions (NRICM102)
This trial tests an herbal medicine called NRICM102 for people with chronic cough and long-term lung diseases like asthma or COPD. It aims to see if the medicine is safe and helps improve symptoms.
Taichung, No.1650, Taiwan Boulevard Sect. 4Ages 18 years+ - NCT06688435RecruitingPhase 1
Immune cell therapy for hard-to-treat myasthenia gravis
This trial tests a new immune cell treatment (CAR T-cells) for people with generalized myasthenia gravis that has not improved with standard treatments. It aims to reduce symptoms by targeting and calming the immune system's attack on muscles.
JinanAges 18–65 - NCT06249919RecruitingPhase 1/Phase 2
Study of NS101 for sudden hearing loss
This trial tests an experimental medicine called NS101 for people who have had a sudden, severe hearing loss in one ear that did not get better with standard steroid treatment. The goal is to see if NS101 can help restore hearing better than steroids alone.
Bucheon-siAges 19–70 - NCT06677229RecruitingPhase 1/Phase 2
Safety and effectiveness of TZ-161 for spinal cord injury
This trial tests a new medicine called TZ-161 in people who have recently had a spinal cord injury in the chest area. The goal is to see if it is safe and can help improve movement.
CórdobaAges 18–65 - NCT06647615Recruiting
Virtual reality for stomach pain in Crohn's disease
This study tests if using a virtual reality (VR) program can help reduce stomach pain in people with Crohn's disease that is not currently active. You will try the VR experience and report how your pain changes.
Jacksonville, FloridaAges 18–70 - NCT06635785RecruitingPhase 1/Phase 2
AI-081 for advanced solid tumors
This trial tests a new drug called AI-081 that targets the immune system and tumor blood vessels. It is for people with advanced solid tumors who have not responded to other treatments or cannot take them.
Birmingham, AlabamaAges 18 years+ - NCT06612775RecruitingPhase 2
Testing CB03-154 for adults with focal epilepsy
This trial tests a new medication, CB03-154, to see if it is safe and can reduce seizures in adults with focal epilepsy. You may be able to join if you have had focal epilepsy for at least 2 years and are on a stable dose of 1 to 3 anti-seizure medications.
Melbourne, VictoriaAges 18–70 - NCT06597006RecruitingPhase 3
Study of inclisiran for children with homozygous familial high cholesterol
This trial tests a new medicine called inclisiran to lower very high cholesterol in children aged 2 to 12 who have a specific genetic condition (homozygous familial hypercholesterolemia, or HoFH). You may not need to change your current cholesterol treatments, and the study will check if inclisiran can help reduce your LDL cholesterol further.
San Francisco, CaliforniaAges 2–11 - NCT06582017RecruitingPhase 1
Study of QXL138AM for advanced solid tumors and multiple myeloma
This trial tests an investigational drug called QXL138AM for people with advanced solid tumors or multiple myeloma that has not responded to standard treatments. The goal is to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT06578624RecruitingPhase 1/Phase 2
SA53-OS for advanced solid tumors
This trial tests an experimental drug (SA53-OS) for people with advanced solid tumors or certain lymphomas whose tumors have a normal p53 gene. The goal is to see if it is safe and helps shrink or slow the cancer.
Canton, OhioAges 18 years+ - NCT06568627RecruitingPhase 3
Testing a gel for cleaning leg ulcers
This study tests a new gel that helps remove dead tissue from venous leg ulcers. Venous leg ulcers are open sores on the leg that happen when veins don't work well. The gel is applied to the ulcer to clean it and help it heal. You may be able to join if you are an adult with a venous leg ulcer that is not too large and has been there for a few weeks.
Phoenix, ArizonaAges 18 years+ - NCT06569602Recruiting
EVOQUE valve study for leaky tricuspid valve
This study is testing a new way to replace the tricuspid valve (the valve that controls blood flow from the heart's right upper chamber to the right lower chamber) without open-heart surgery. The goal is to see how safe and effective the EVOQUE valve is for people with a leaky tricuspid valve.
Bad BerkaAges Any age - NCT06552598RecruitingPhase 1
KD01 for advanced gynecologic cancers
This trial tests a new drug called KD01 for women with advanced gynecologic cancers (like cervical or endometrial cancer) that haven't responded to other treatments. It also has a separate part for younger women who want to preserve their fertility.
Wuhan, HubeiAges 18 years+ - NCT06539624Recruiting
Testing a new gene therapy for Fabry disease
This trial is testing a new treatment called EXG110 for people with Fabry disease. It's designed to see if it's safe and if it can help. You may be able to join if you have a confirmed diagnosis and at least one symptom of Fabry disease.
Shanghai, Shanghai MunicipalityAges 7 years+
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,733 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.